Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Disruptive Materials is a Swedish biotechnology and materials science company specializing in the development of Upsalite, a unique mesoporous magnesium carbonate. The company's primary focus in the healthcare sector is enhancing the bioavailability of poorly soluble drugs by stabilizing them in an amorphous state within the pores of Upsalite. This platform technology allows for higher drug loading and faster dissolution rates compared to traditional delivery methods. Disruptive Materials operates through partnerships with pharmaceutical companies to reformulate existing and new drug candidates. Additionally, the company commercializes its material for use in professional sports and high-end cosmetics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Disruptive Materials.